Hanyu Pharmaceutical announced that the company cooperated with Shenzhen Tanyunzhi Peptide Pharmaceutical Technology Co., Ltd. to develop HY3003 injections for weight loss indications. The company recently received the “Notice of Acceptance” for clinical trial applications approved and issued by the State Drug Administration. The acceptance numbers are CXHL2601095, CXHL2601096, CXHL2601097, CXHL2601098, CXHL2601099, and CXHL2601100.

Zhitongcaijing · 2d ago
Hanyu Pharmaceutical announced that the company cooperated with Shenzhen Tanyunzhi Peptide Pharmaceutical Technology Co., Ltd. to develop HY3003 injections for weight loss indications. The company recently received the “Notice of Acceptance” for clinical trial applications approved and issued by the State Drug Administration. The acceptance numbers are CXHL2601095, CXHL2601096, CXHL2601097, CXHL2601098, CXHL2601099, and CXHL2601100.